With the ongoing shortage of Wegovy (semaglutide) and Ozempic, Gambi-tang herbal prescriptions are attracting attention as a practical alternative. While GLP-1 agonists work through a single pathway of appetite suppression and delayed gastric emptying, Gambi prescriptions stimulate multiple pathways including metabolic enhancement, water regulation, and caloric breakdown. A 2022 Korean medicine study in an SCI-level journal reported an average weight loss of 4.8 kg over 12 weeks in the Gambi-hwan group. Based on natural herbs with thousands of years of clinical history, these formulations offer stable supply and cost accessibility — and can be started on the day of the initial telemedicine consultation, anywhere in the country.